Experiment 1028823
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | FONG,KLL: HO,DHW: BENJAMIN,RS: BROWN,NS: BEDIKIAN,A: YAP,BS: WISEMAN,CL: KRAMER,W: BODEY,GP:. (1982). CLINICAL PHARMACOLOGY OF BRUCEANTIN BY RADIOIMMUNOASSAY.. 9() |
| Amount utilized | |
| Compound isolated | |
| Disease | THE PHARMACOLOGY OF THE TITLE COMPOUND WAS STUDIED IN 18 CANCER PATIENTS DURING A PHASE I STUDY.THE DRUG WAS INFUSED FOR 3 HOURS AT DOSES RANGING FROM 1 TO 3.6 MG/SQ METER PER DAY FOR 5 DAYS. THE PLASMA DRUG DISAPPEARANCE CURVES WERE BIPHASIC WITH A FAST INITAL HALF-LIFE OF LESS THAN 15 MINUTES. THE SECOND HALF-LIFE VARIED FROM 0.7 TO 38 HOURS AMONG DIFFERENT PATIENTS AND WAS NOT DOSE-RELATED. PATIENTS WITH ABNORMAL LIVER FUNCTION DEVELOPED MORE SEVERE TOXICITY,INCLUDING FEVER,SEVERE NAUSEA,VOMITING AND HYPOTENSION. 2 PATIENTS WITH SEVERE HEPATIC DYSFUNCTION RECEIVED A REDUCED DOSE AND DEVELOPED NO TOXICITY. THESE RESULTS DEMONSTRATED THE IMPORTANCE OF THE EFFECTS OF LIVER DYSFUNCTION ON DRUG DISPOSITION AND SHOWED THAT THE DOSAGE SHOULD BE REDUCED IN PATIENTS WITH HEPATIC DYSFUNCTION. |
| Dose amount | 1-3.6 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |